🇺🇸 FDA
Pipeline program

EBVALLO

ATA129-EBV-302

Phase 3 small_molecule active

Quick answer

EBVALLO for Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease is a Phase 3 program (small_molecule) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).

Program details

Company
Pierre Fabre Medicament
Indication
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials